drugset / Trial / NCT00004052
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
Phase 2
Completed
24 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
Timeline
- Start
- 1999-03
- Primary completion
- 2005-08
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bcr/abl breakpoint peptide vaccine | Vaccine | — | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |